Screening and monitoring patients with COVID-19 pneumonia treated with immunosuppressive agents for hepatitis B reactivation.
Kanzo/Acta Hepatologica Japonica
; 63(10):463-464, 2022.
Artículo
en Japonés
| EMBASE | ID: covidwho-20239451
ABSTRACT
Immunosuppressive drugs are used for treating coronavirus disease 2019COVID-19pneumonia. This study examined the current status of screening and monitoring patients with COVID-19 pneumonia treated with immunosuppressive agents for hepatitis B virusHBVreactivation. Of 123 patients whose hepatitis B surface antigen level was measured, 2 were HBsAg-positive. Antihepatitis B core/surface antibodies were measured in all 121 HBsAg-negative patients. HBV DNA was measured in 31 of 32 patients who were positive for either or both antihepatitis B core/surface antibodies. Of 34 patients requiring regular monitoring, only 4 were monitored. The HBV monitoring rate at the initiation of COVID-19 treatment was high. How-ever, HBV monitoring after COVID-19 treatment was difficult because most patients were transferred to other hospitals or had their treatment terminated.Copyright © 2022 Takeshi Matsui et al.
covid-19; HBV reactivation; immunosuppressive therapy; article; coronavirus disease 2019/di [Diagnosis]; coronavirus disease 2019/dt [Drug Therapy]; hepatitis B/di [Diagnosis]; human; immunosuppressive treatment; major clinical study; monitoring; screening; virus reactivation; hepatitis B core antibody; hepatitis B surface antigen; immunosuppressive agent/dt [Drug Therapy]; virus DNA
Texto completo:
Disponible
Colección:
Bases de datos de organismos internacionales
Base de datos:
EMBASE
Idioma:
Japonés
Revista:
Acta Hepatologica Japonica
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS